Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
One of the persistent criticisms of early ketamine research was the lack of a convincing placebo. Ketamine produces noticeable dissociative and psychoactive effects, which means patients receiving it can often tell they're not getting saline. If patients know they've received the active drug, expectation bias can inflate apparent efficacy. A 2013 two-site trial tackled this problem head-on by comparing ketamine to midazolam — a benzodiazepine that produces sedation without antidepressant effects.
James Murrough and colleagues conducted a randomized, double-blind trial at two academic medical centers, published in the American Journal of Psychiatry in 2013. Seventy-three patients with treatment-resistant major depression were randomized 2:1 to receive a single intravenous infusion of either ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg). The 2:1 randomization was chosen to maximize the number of patients receiving the experimental treatment while maintaining adequate statistical power for the control group.
Midazolam was selected as the active comparator specifically because it produces sedation, mild euphoria, and some subjective effects — making it more difficult for participants to guess their assignment compared to saline placebo. This addresses the blinding concern that has dogged many ketamine studies.
The primary outcome was response at 24 hours, defined as a 50% or greater reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) score. Ketamine produced a response rate of 64%, compared to 28% for midazolam — a statistically significant difference. The effect was rapid, with separation between groups evident within hours of infusion. Secondary analyses showed that ketamine's benefits extended across multiple symptom domains, including mood, anhedonia, and suicidal ideation.
This trial is one of the strongest pieces of evidence supporting ketamine's antidepressant efficacy because of its methodological rigor. The use of an active comparator makes it much harder to attribute the results to placebo effects or expectancy bias. The 64% response rate in a treatment-resistant population — patients who had failed, on average, multiple prior antidepressant trials — is notable by any standard.
For clinicians weighing the evidence on ketamine, the Murrough trial provides a level of confidence that goes beyond earlier saline-controlled studies. It suggests that ketamine's effects are pharmacological, not merely psychological. The multi-site design also adds generalizability — the results weren't confined to a single research team or patient population.
It is worth noting that, like other single-dose studies, the benefits were time-limited. Most patients experienced symptom return within one to two weeks. This is consistent with the broader ketamine literature and underscores the importance of repeated dosing protocols and integration with ongoing therapy.
If you've been skeptical about whether ketamine's effects are "real" or simply due to the unusual experience of the drug, this study provides reassurance. When compared against another psychoactive sedative — one that also produces noticeable effects — ketamine still demonstrated significantly greater antidepressant response.
For patients with treatment-resistant depression, a 64% response rate within 24 hours represents a meaningful option, especially when standard medications have not worked. Ketamine is not a one-time fix; most treatment protocols involve a series of sessions. But the evidence from this trial suggests that the rapid relief many patients experience is grounded in genuine pharmacological action.
In a well-controlled trial comparing ketamine to the active placebo midazolam, ketamine produced significantly greater antidepressant response at 24 hours in patients with treatment-resistant depression. This study strengthens the case that ketamine's rapid effects are pharmacological rather than driven by expectancy or placebo.
Reference: Murrough JW, Iosifescu DV, Chang LC, et al. "Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial." American Journal of Psychiatry. 2013;170(10):1134-1142. PMID: 23982301
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
